F-10POS: Oncolytics Biotech Deregisters Unsold Securities
Securities Deregistration
Oncolytics Biotech Inc. has filed post-effective amendments to withdraw multiple Form F-10 registration statements, deregistering unsold portions of various securities.
Summary
- Oncolytics Biotech Inc. is withdrawing ten previously filed Form F-10 Registration Statements with the U.S. Securities and Exchange Commission (SEC).
- This action deregisters the unsold portions of securities that were registered under these statements, including units, common shares, subscription receipts, warrants, and debt securities.
- The registration statements being withdrawn date back as far as February 2, 2007, and as recently as July 25, 2024.
- The deregistration is scheduled to become effective on April 7, 2026, at 10:00 p.m. Eastern time, pursuant to Rule 467(b).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral administrative filing, neither positive nor negative for the company's immediate operational or financial prospects. It is a routine regulatory cleanup.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the company's future operational or financial performance.
Management Comments
- Jared Kelly, Chief Executive Officer, certified that the company has reasonable grounds to believe it meets all requirements for filing on Form F-10 and duly caused the post-effective amendments to be signed on its behalf.
Industry Context
StockSavvy.ai notes that administrative filings like this are common for companies that have previously registered a shelf offering but did not utilize the full amount of registered securities. It indicates a cleanup of regulatory records rather than a change in operational strategy or a new capital markets event.
Stakeholder Impact
- Shareholders may infer that the company does not currently intend to issue additional shares under these specific old registrations, which could be seen as reducing potential dilution from those particular shelf offerings. However, this does not preclude future capital raises under new registration statements.
Next Steps
- The deregistration of the unsold securities will become effective on April 7, 2026, at 10:00 p.m. Eastern time.
Key Dates
| Date | Description |
|---|---|
| February 2, 2007 | Initial filing of Registration Statement No. 333-140460 by Oncolytics Biotech Inc. |
| February 8, 2007 | Initial filing of Registration Statement No. 333-140529 by Oncolytics Biotech Inc. |
| June 6, 2008 | Initial filing of Registration Statement No. 333-151513 by Oncolytics Biotech Inc. |
| June 2, 2010 | Initial filing of Registration Statement No. 333-167250 by Oncolytics Biotech Inc. |
| June 21, 2012 | Initial filing of Registration Statement No. 333-182260 by Oncolytics Biotech Inc. |
| July 25, 2014 | Initial filing of Registration Statement No. 333-197633 by Oncolytics Biotech Inc. |
| April 25, 2018 | Initial filing of Registration Statement No. 333-224432 by Oncolytics Biotech Inc. |
| June 8, 2020 | Initial filing of Registration Statement No. 333-239025 by Oncolytics Biotech Inc. |
| June 10, 2022 | Initial filing of Registration Statement No. 333-265510 by Oncolytics Biotech Inc. |
| July 25, 2024 | Initial filing of Registration Statement No. 333-281009 by Oncolytics Biotech Inc. |
| March 31, 2026 | Filing date of the Post-Effective Amendment No. 1 to Form F-10. |
| April 7, 2026 | Effective date of the deregistration of securities. |
Recommendation
holdThis administrative filing to deregister unsold securities from old shelf registrations does not provide any new material information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. It is a routine regulatory cleanup.
Keywords
Oncolytics Biotech, SEC filing, F-10POS, deregistration, securities withdrawal, capital markets, regulatory compliance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.